Insomnia - Opportunity Assessment and Forecast

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the insomnia market through 2032.

Insomnia, currently represented in the International Classification of Sleep Disorders (Third Edition; ICSD-3) and the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition; DSM-5), is defined as patient-reported difficulty with sleep initiation or sleep maintenance, despite adequate opportunity and circumstances for sleep. It can include frequent awakenings, difficulty returning to sleep after awakening, or awakening too early with the inability to return to sleep, which impair physical and cognitive function during the daytime. These symptoms may occur in isolation or together, and the presentation may vary over time.

GlobalData anticipates the global insomnia market-which, for the purpose of this report, comprises seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, Japan)-will experience steady growth during the forecast period. This growth will be driven primarily by the anticipated arrival of pipeline products: EUSOL Biotech's SM-1, Taisho Pharmaceutical's vornorexant, Imbrium Therapeutics' sunobinop, and Vanda Pharmaceuticals' Hetlioz. Nevertheless, looming patent expiries are expected to curtail market growth.

This model covers the market forecast for insomnia therapies and late-stage pipeline candidates. The base year of this model is 2022 and the forecast period is 2022-32.

Scope

• Overview of insomnia, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized insomnia treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the insomnia therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for insomnia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global insomnia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global insomnia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global insomnia therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.